Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ovarian Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 60 articles: HTML format

Single Articles

April 2024
1. MUTLU SUTCUOGLU B, Sutcuoglu O
   Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant Chemotherapy Have an Effect on Disease Outcome?
   J Clin Oncol. 2024;42:1204-1205.
   PubMed    
   
   
   
2. HAN CY, Lu KH, Corrigan G, Perez A, et al
   Normal Risk Ovarian Screening Study: 21-Year Update.
   J Clin Oncol. 2024;42:1102-1109.
   PubMed     Abstract available
   
   
   February 2024
3. LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al
   Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
   J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225.
   PubMed     Abstract available
   
   
   
4. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
   Compelling Story of Ovarian Cancer Screening.
   J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
   PubMed    
   
   
   January 2024
5. TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al
   Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
   J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182.
   PubMed     Abstract available
   
   
   November 2023
6. LAVERY JA, Boutros PC, Scott JM, Tammela T, et al
   Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality.
   J Clin Oncol. 2023;41:4982-4992.
   PubMed     Abstract available
   
   
   
7. ST LAURENT J, Liu JF
   Treatment Approaches for Platinum-Resistant Ovarian Cancer.
   J Clin Oncol. 2023 Nov 1:JCO2301771. doi: 10.1200/JCO.23.01771.
   PubMed     Abstract available
   
   
   October 2023
8. AREND RC, Monk BJ, Shapira-Frommer R, Haggerty AF, et al
   Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
   J Clin Oncol. 2023 Oct 31:JCO2202915. doi: 10.1200/JCO.22.02915.
   PubMed     Abstract available
   
   
   September 2023
9. OZOLS RF, Bundy BN, Greer BE, Fowler JM, et al
   Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
   J Clin Oncol. 2023;41:4077-4083.
   PubMed     Abstract available
   
   
   
10. SPRIGGS DR, Fleming GF
    Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer.
    J Clin Oncol. 2023;41:4063-4064.
    PubMed    
    
    
    August 2023
11. KURTZ JE, Pujade-Lauraine E, Oaknin A, Belin L, et al
    Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
    J Clin Oncol. 2023 Aug 29:JCO2300529. doi: 10.1200/JCO.23.00529.
    PubMed     Abstract available
    
    
    
12. MCCAW ZR, Tian L, Wei LJ
    Evaluating the Duration of Response With Mirvetuximab Soravtansine for Treating Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Aug 3:JCO2300288. doi: 10.1200/JCO.23.00288.
    PubMed    
    
    
    June 2023
13. COLOMBO N, Van Gorp T, Matulonis UA, Oaknin A, et al
    Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
    J Clin Oncol. 2023 Jun 26:JCO2202624. doi: 10.1200/JCO.22.02624.
    PubMed     Abstract available
    
    
    May 2023
14. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    PubMed     Abstract available
    
    
    
15. STROOT IAS, Brouwer J, Bart J, Hollema H, et al
    High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.
    J Clin Oncol. 2023;41:2523-2535.
    PubMed     Abstract available
    
    
    March 2023
16. FU S, Yao S, Yuan Y, Previs RA, et al
    Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
    J Clin Oncol. 2023;41:1725-1734.
    PubMed     Abstract available
    
    
    February 2023
17. SUN R, Huang B, Wei LJ
    Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer.
    J Clin Oncol. 2023 Feb 10:JCO2202596. doi: 10.1200/JCO.22.02596.
    PubMed    
    
    
    January 2023
18. MATULONIS UA, Lorusso D, Oaknin A, Pignata S, et al
    Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
    J Clin Oncol. 2023 Jan 30:JCO2201900. doi: 10.1200/JCO.22.01900.
    PubMed     Abstract available
    
    
    
19. CRABB SJ, Hussain S, Soulis E, Hinsley S, et al
    A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:54-64.
    PubMed     Abstract available
    
    
    
20. YOU B, Sehgal V, Hosmane B, Huang X, et al
    CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    J Clin Oncol. 2023;41:107-116.
    PubMed     Abstract available
    
    
    December 2022
21. KINDLER HL, Hammel P, Reni M, Van Cutsem E, et al
    Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    J Clin Oncol. 2022;40:3929-3939.
    PubMed     Abstract available
    
    
    November 2022
22. ZHANG J, Liu M
    Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.
    J Clin Oncol. 2022;40:3783.
    PubMed    
    
    
    
23. PFISTERER J, Joly F, Kristensen G, Rau J, et al
    Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
    J Clin Oncol. 2022 Nov 4:JCO2201010. doi: 10.1200/JCO.22.01010.
    PubMed     Abstract available
    
    
    October 2022
24. YOU B, Purdy C, Copeland LJ, Swisher EM, et al
    Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
    J Clin Oncol. 2022 Oct 17:JCO2201207. doi: 10.1200/JCO.22.01207.
    PubMed     Abstract available
    
    
    
25. MARCHETTI C, Fagotti A, Scambia G
    Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.
    J Clin Oncol. 2022 Oct 6:JCO2201585. doi: 10.1200/JCO.22.01585.
    PubMed    
    
    
    September 2022
26. TEW WP, Lacchetti C, Kohn EC
    Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Sep 23:JCO2201934. doi: 10.1200/JCO.22.01934.
    PubMed     Abstract available
    
    
    
27. DISILVESTRO P, Banerjee S, Colombo N, Scambia G, et al
    Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
    J Clin Oncol. 2022 Sep 9:JCO2201549. doi: 10.1200/JCO.22.01549.
    PubMed     Abstract available
    
    
    
28. TANYI JL, Randall LM, Chambers SK, Butler KA, et al
    A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
    J Clin Oncol. 2022 Sep 7:JCO2200291. doi: 10.1200/JCO.22.00291.
    PubMed     Abstract available
    
    
    August 2022
29. SPILSBURY K, Tuesley KM, Pearson SA, Coory MD, et al
    Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions.
    J Clin Oncol. 2022 Aug 24:JCO2200097. doi: 10.1200/JCO.22.00097.
    PubMed     Abstract available
    
    
    
30. HAMPEL H, Yurgelun MB
    Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
    J Clin Oncol. 2022;40:2681-2692.
    PubMed     Abstract available
    
    
    
31. FU S, Corr BR, Culm-Merdek K, Mockbee C, et al
    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
    J Clin Oncol. 2022;40:2568-2577.
    PubMed     Abstract available
    
    
    
32. LI N, Zhang Y, Wang J, Zhu J, et al
    Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    J Clin Oncol. 2022;40:2436-2446.
    PubMed     Abstract available
    
    
    July 2022
33. HURWITZ LM, Townsend MK, Jordan SJ, Patel AV, et al
    Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
    J Clin Oncol. 2022 Jul 22:JCO2101900. doi: 10.1200/JCO.21.01900.
    PubMed     Abstract available
    
    
    
34. BETANCOURT NJ, Qian MF, Pickford JR, Bailey-Healy I, et al
    Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity.
    J Clin Oncol. 2022;40:2119-2127.
    PubMed     Abstract available
    
    
    June 2022
35. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.
    PubMed    
    
    
    
36. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed     Abstract available
    
    
    
37. MONK BJ, Parkinson C, Lim MC, O'Malley DM, et al
    A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
    J Clin Oncol. 2022 Jun 6:JCO2201003. doi: 10.1200/JCO.22.01003.
    PubMed     Abstract available
    
    
    May 2022
38. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
    PubMed    
    
    
    
39. LIEBERMAN S, Goldvaser H, Levy-Lahad E
    Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    J Clin Oncol. 2022;40:1590-1594.
    PubMed    
    
    
    
40. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
    J Clin Oncol. 2022;40:1529-1541.
    PubMed     Abstract available
    
    
    
41. DONOVAN HS, Sereika SM, Wenzel LB, Edwards RP, et al
    Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).
    J Clin Oncol. 2022;40:1464-1473.
    PubMed     Abstract available
    
    
    March 2022
42. POWELL MA, Filiaci VL, Hensley ML, Huang HQ, et al
    Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
    J Clin Oncol. 2022;40:968-977.
    PubMed     Abstract available
    
    
    
43. LIU JF, Brady MF, Matulonis UA, Miller A, et al
    Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
    J Clin Oncol. 2022 Mar 15:JCO2102011. doi: 10.1200/JCO.21.02011.
    PubMed     Abstract available
    
    
    
44. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
    PubMed     Abstract available
    
    
    February 2022
45. BAEK MH, Park EY, Ha HI, Park SY, et al
    Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis.
    J Clin Oncol. 2022 Feb 21:JCO2102085. doi: 10.1200/JCO.21.02085.
    PubMed     Abstract available
    
    
    
46. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
    Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
    J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
    PubMed     Abstract available
    
    
    January 2022
47. BILASH T, Walker LM
    Spare Parts: Navigating Ovarian Cancer as a Transgender Man.
    J Clin Oncol. 2022 Jan 12:JCO2101249. doi: 10.1200/JCO.21.01249.
    PubMed    
    
    
    December 2021
48. MO DC, Ren T
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2021 Dec 10:JCO2102208. doi: 10.1200/JCO.21.02208.
    PubMed    
    
    
    September 2021
49. PORTER RL, Matulonis UA
    Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.
    J Clin Oncol. 2021 Sep 16:JCO2101886. doi: 10.1200/JCO.21.01886.
    PubMed    
    
    
    
50. HAMANISHI J, Takeshima N, Katsumata N, Ushijima K, et al
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
    J Clin Oncol. 2021 Sep 2:JCO2100334. doi: 10.1200/JCO.21.00334.
    PubMed     Abstract available
    
    
    May 2021
51. ZIVANOVIC O, Chi DS, Zhou Q, Iasonos A, et al
    Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
    J Clin Oncol. 2021 May 21:JCO2100605. doi: 10.1200/JCO.21.00605.
    PubMed     Abstract available
    
    
    April 2021
52. MOORE KN, Bookman M, Sehouli J, Miller A, et al
    Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    J Clin Oncol. 2021 Apr 23:JCO2100306. doi: 10.1200/JCO.21.00306.
    PubMed     Abstract available
    
    
    
53. KONSTANTINOPOULOS PA, Cannistra SA
    Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
    J Clin Oncol. 2021 Apr 23:JCO2100571. doi: 10.1200/JCO.21.00571.
    PubMed    
    
    
    February 2021
54. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    PubMed     Abstract available
    
    
    November 2020
55. MONK BJ, Grisham RN, Banerjee S, Kalbacher E, et al
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    J Clin Oncol. 2020;38:3753-3762.
    PubMed     Abstract available
    
    
    October 2020
56. OZA AM, Lorusso D, Aghajanian C, Oaknin A, et al
    Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    J Clin Oncol. 2020;38:3494-3505.
    PubMed     Abstract available
    
    
    August 2020
57. PAULINO E, Melo AC
    SOLO 3 Trial: How Do the Results Fit in With Current Evidence?
    J Clin Oncol. 2020;38:2697-2698.
    PubMed    
    
    
    
58. PENSON RT, Lowe ES
    Reply to E. Paulino et al.
    J Clin Oncol. 2020;38:2698.
    PubMed    
    
    
    March 2020
59. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    PubMed     Abstract available
    
    
    
60. YANG X, Leslie G, Doroszuk A, Schneider S, et al
    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
    J Clin Oncol. 2020;38:674-685.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.